Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5606_Библиотеки_им_академика_М_И_Перельмана.pdf
12 Experimental Assays: Chemical Properties, Biochemical and... 367
predictions aiming to prioritize which inhibitors or potential repurposing drugs
would be experimentally validated in vitro and ultimately tested in vivo [309, 310].
6 In Vivo Evaluation of Compounds
In general, in vivo evaluation is the third step of a pipeline for bioactive compounds
screening (in silico, in vitro, and in vivo, respectively) [311]. The most widely used
experimental models used for in vivo assays are mice, used to validate in vitro tests
and observe efficacy in whole organisms. This model has advantages such as fast
procreation, low cost, easy maneuver and care, the option for using inbred or outbred
animals, the possibility of knock-in and knockout animals, and a diversity of
background options for making them susceptible for human infectious diseases
[312, 313]. Similar to in vitro assays, toxicity should be assessed in vivo, which
translates to assessing lethal dose of 50% (DL
chosen animal model, usually by assessing different compound or drug concentrations (mg/kg) tolerated by the animal. Afterwards, one should determine or choose
the most suit able concentration range as well as the pathogens’ infection parameters
[314, 315].
In this sense, regarding a compound concentration, solubility may play a key role
in oral absorption, as poor aqueous solubility may be decisive in drug discovery
studies, including in translating in vitro to in vivo [316] and different experimental
evaluation approaches [317], potentially requiring another round of lead optimization or failing a given drug candidate [318]. PK modeling based on validated data
may help with many different approaches and their implications regarding aqueous
solubility, including temperature, pH-dependency, and ultimately bioavailability
[136, 318]. As for pathogens, researchers can also use mouse models for analyzing
infection effects directly and indirectly. These models can be used for testing drug
protection against lethality, or to test mitigation of an infection and/or disease by a
given compound or drug, thus evaluating the animal response or reestablishment
against an infection [319, 320]. Different mice and other murine models can be used
for specific pathogenic infections or can be standardized in the laboratory. Herein,
one should consider a variety of parameters such as pathogen inoculum, route of
infection, clinical score of disease, difference between genetic backgrounds, age and
gender, and the necessity of genetic modification to make the animal susceptible for
a specific infectious disea se [235, 321].
Notwithstanding, even if solubility and infection issues are overcome, compounds that are correctly predicted for a given target should still be validated
concerning their ability to ultimately display the desired activity, while also permeating cell membranes or tissue barriers [228]. Predictions in this sense should also
consider the specificity and stability of compounds, as well as previously assessing
predictions for the potential ADMET and PK properties [18]. Despite the fact that
ADMET simulations are more directed at translating in vitro experimentally determined effect to in vivo [317], they also aim to potentially increase the success rate of
) or tolerability assays of drugs in the
50
368 M. Sá Magalhães Serafim et al.
predicted hits as favorable compounds for optimization, which could ultimately
reach a potential lead candidate and become a drug [202]. These aspects are
important to reduce the risks in the late drug discovery stages and also optimize
the bridging between computational simulations, and experimental validations,
focusing on promising compounds [322].
7 Conclusions
Considering the field of drug design and discovery, the search for novel drugs
requires a lasting effort to tackle long known, emerging, or re-emerging diseases.
The focus on targets of interest, such as enzymes, may be a starting point for
discovery campaigns. In this sense, designing and develo ping potential inhibitors
and lead drug candidates should account for PK and ADMET, as well as cytotoxicity. Moreover, if related to an infectious disease, as in the search for antivirals,
antibacterials, and antifungals, it is essential to focus on selectivity and specificity.
Here, the combination of in silico, in vitro, and in vivo approaches is an important
triad to any drug discovery campaign that can encompass compounds’ chemical
properties, biochemical and cellular assays, and in vivo evaluation to reach a
successful drug candidate. Although challenging, many options are available to
translate different computational simulations into various experimental validations.
Examples include the discovery of some protease inhibitors, such as nirmatrelvir,
and recently ensitrelvir, successfully obtained by combining computer-aided
approaches and experimental assays. Herein, we discussed the possibilities and
feasibility, challenges and pitfalls, and the current scenario of such computational
approaches that, especially when combined, may contribute to a successful protocol
in drug discovery.
References
1. Wouters, O. J., McKee, M., & Luyten, J. (2020). Estimated Research and Development
investment needed to bring a new medicine to market, 2009–2018. JAMA, 323, 844–853.
2. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical
industry: New estimates of R&D costs. Journal of Health Economics, 47,20–33.
3. Prasad, V., & Mailankody, S. (2017). Research and development spending to bring a single
cancer drug to market and revenues after approval. JAMA Internal Medicine, 177, 1569–1575.
4. Cummings, E. (2019). The Elijah E. Cummings Lower Drug Costs Now Act: how it would
work, how it would affect prices, and what the challenges are – Digital Collections – National
Library of Medicine. https://collections.nlm.nih.gov/catalog/nlm:nlmuid-101769556-pdf
5. Sun, D., Gao, W., Hu, H., & Zhou, S. (2022). Why 90% of clinical drug development fails and
how to improve it? Acta Pharmaceutica Sinica B, 12, 3049–3062.
6. Sadybekov, A. V., & Katritch, V. (2023). Computational approaches streamlining drug
discovery. Nature, 616, 673–685.
12 Experimental Assays: Chemical Properties, Biochemical and... 369
7. Gramatica, P. (2020). Principles of QSAR modeling: Comments and suggestions from personal experience. International Journal of Quantitative Structure-Property Relationships, 5,
61–97.
8. Wassermann, A. M., Wawer, M., & Bajorath, J. (2010). Activity landscape representations for
structure-Activity relationship analysis. Journal of Medicinal Chemistry, 53, 8209–8223.
9. Lin, X., Li, X., & Lin, X. (2020). A review on applications of computational methods in drug
screening and design. Molecules, 25, 1375.
10. Rodríguez-Pérez, R., & Bajorath, J. (2021). Evaluation of multi-target deep neural network
models for compound potency prediction under increasingly challenging test conditions.
Journal of Computer-Aided Molecular Design, 35, 285–295.
11. Boobier, S., Hose, D. R. J., Blacker, A. J., & Nguyen, B. N. (2020). Machine learning with
physicochemical relationships: Solubility prediction in organic solvents and water. Nature
Communications, 11, 5753.
12. Feinberg, E. N., Joshi, E., Pande, V. S., & Cheng, A. C. (2020). Improvement in ADMET
prediction with multitask deep featurization. Journal of Medicinal Chemistry, 63, 8835–8848.
13. Jiménez-Luna, J., Grisoni, F., & Schneider, G. (2020). Drug discovery with explainable
artificial intelligence. Nature Machine Intelligence, 2, 573–584.
14. Jumper, J., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature,
596, 583–589.
15. Varadi, M., & Velankar, S. (2023). The impact of AlphaFold protein structure database on the
fields of life sciences. Proteomics, 23, 2200128.
16. Kiriiri, G. K., Njogu, P. M., & Mwangi, A. N. (2020). Exploring different approaches to
improve the success of drug discovery and development projects: A review. Future Journal of
Pharmaceutical Sciences, 6, 27.
17. Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019). Concepts of artificial
intelligence for computer-assisted drug discovery. Chemical Reviews, 119, 10520–10594.
18. Pantaleão, S. Q., Fernandes, P. O., Gonçalves, J. E., Maltarollo, V. G., & Honorio, K. M.
(2022). Recent advances in the prediction of pharmacokinetics properties in drug design
studies: A review. ChemMedChem, 17, e202100542.
19. Engeloch, C., et al. (2008). Stability of screening compounds in wet DMSO. SLAS Discovery,
13, 999–1006.
20. Nurzyńska, K., et al. (2015). Long-term amorphous drug stability predictions using easily
calculated, predicted, and measured parameters. Molecular Pharmaceutics, 12, 3389–3398.
21. Bergström, C. A. S., Charman, W. N., & Porter, C. J. H. (2016). Computational prediction of
formulation strategies for beyond-rule-of-5 compounds. Advanced Drug Delivery Reviews,
101,6–21.
22. Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014). Computational methods in drug
discovery. Pharmacological Reviews, 66, 334–395.
23. Jayatunga, M. K. P., Xie, W., Ruder, L., Schulze, U., & Meier, C. (2022). AI in smallmolecule drug discovery: A coming wave? Nature Reviews Drug Discovery, 21
24. Thakkar, A., et al. (2021). Artificial intelligence and automation in computer aided synthesis
planning. Reaction Chemistry & Engineering, 6,27–51.
25. Sadybekov, A. A., et al. (2022). Synthon-based ligand discovery in virtual libraries of over
11 billion compounds. Nature, 601, 452–459.
26. Gorgulla, C., et al. (2020). An open-source drug discovery platform enables ultra-large virtual
screens. Nature, 580, 663–668.
27. Muratov, E. N., et al. (2021). A critical overview of computational approaches employed for
COVID-19 drug discovery. Chemical Society Reviews, 50, 9121–9151.
28. Galindez, G., et al. (2021). Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. Nature Computational Science, 1,33–41.
29. Unoh, Y., et al. (2022). Discovery of S-217622, a noncovalent Oral SARS-CoV-2 3CL
protease inhibitor clinical candidate for treating COVID-19. Journal of Medicinal Chemistry,
65, 6499–6512.
, 175–176.
370 M. Sá Magalhães Serafim et al.
30. Gentile, F., Oprea, T. I., Tropsha, A., & Cherkasov, A. (2023). Surely you are joking, Mr
docking! Chemical Society Reviews, 52, 872–878.
31. Ruatta, S. M., et al. (2023). Garbage in, garbage out: How reliable training data improved a
virtual screening approach against SARS-CoV-2 MPro. Frontiers in Pharmacology, 14.
32. Jafari, M., Guan, Y., Wedge, D. C., & Ansari-Pour, N. (2021). Re-evaluating experimental
validation in the big data era: A conceptual argument. Genome Biology, 22, 71.
33. Chowdhury, A. S., Reehl, S. M., Kehn-Hall, K., Bishop, B., & Webb-Robertson,
B.-J. M. (2020). Better understanding and prediction of antiviral peptides through primary
and secondary structure feature importance. Scientific Reports, 10, 19260.
34. Strittmatter, S. M. (2014). Overcoming drug development bottlenecks with repurposing: Old
drugs learn new tricks. Nature Medicine, 20, 590–591.
35. Lu, M., Xing, H., Zheng, A., Huang, Y., & Liang, X.-J. (2023). Overcoming pharmaceutical
bottlenecks for nucleic acid drug development. Accounts of Chemical Research, 56, 224–236.
36. Yamada, Y. (2021). Nucleic acid drugs—Current status, issues, and expectations for
exosomes. Cancers (Basel), 13, 5002.
37. (2023). Experimental validation, anyone? Nature Computational Science, 3, 361–361.
38. Serafim, M. S. M., et al. (2023). The importance of good practices and false hits for QSARdriven virtual screening real application: A SARS-CoV-2 main protease (Mpro) case study.
Frontiers in Drug Discovery, 3.
39. Deshmukh, M. G., et al. (2021). Structure-guided design of a perampanel-derived
pharmacophore targeting the SARS-CoV-2 main protease. Structure, 29, 823–833.e5.
40. Bespalov, A., Steckler, T., & Skolnick, P. (2019). Be positive about negativesrecommendations for the publication of negative (or null) results. European
Neuropsychopharmacology, 29, 1312–1320.
41. Nimpf, S., & Keays, D. A. (2020). Why (and how) we should publish negative data. EMBO
Reports, 21, e49775.
42. Maxim, L. D., Niebo, R., & Utell, M. J. (2014). Screening tests: A review with examples.
Inhalation Toxicology, 26, 811–828.
43. Veríssimo, G. C., et al. (2022). Designing drugs when there is low data availability: One-shot
learning and other approaches to face the issues of a long-term concern. Expert Opinion on
Drug Discovery, 17, 929–947.
44. Tropsha, A. (2010). Best practices for QSAR model development, validation, and exploitation.
Molecular Informatics, 29, 476–488.
45. Macip, G., et al. (2022). A review of the current landscape of SARS-CoV-2 Main protease
inhibitors: Have we hit the Bullseye yet? International Journal of Molecular Sciences,
23, 259.
46. Bajorath, J., et al. (2020). Artificial intelligence in drug discovery: Into the great wide open.
Journal of Medicinal Chemistry, 63, 8651–8652.
47. Graff, D. E., Shakhnovich, E. I., & Coley, C. W. (2021). Accelerating high-throughput virtual
screening through molecular pool-based active learning. Chemical Science, 12, 7866–
48. Williams, A. J., & Ekins, S. (2011). A quality alert and call for improved curation of public
chemistry databases. Drug Discovery Today, 16, 747–750.
49. Frye, L., Bhat, S., Akinsanya, K., & Abel, R. (2021). From computer-aided drug discovery to
computer-driven drug discovery. Drug Discovery Today: Technologies, 39, 111–117.
50. de Souza Neto, L. R., et al. (2020). In silico strategies to support fragment-to-Lead optimization in drug discovery. Frontiers in Chemistry, 8.
51. Hollingsworth, S. A., & Dror, R. O. (2018). Molecular dynamics simulation for all. Neuron,
99, 1129–1143.
52. Kapla, J., Rodríguez-Espigares, I., Ballante, F., Selent, J., & Carlsson, J. (2021). Can molecular dynamics simulations improve the structural accuracy and virtual screening performance
of GPCR models? PLoS Computational Biology, 17, e1008936.
53. Jarmoskaite, I., AlSadhan, I., Vaidyanathan, P. P., & Herschlag, D. (2020). How to measure
and evaluate binding affinities. eLife, 9, e57264.
7881.
12 Experimental Assays: Chemical Properties, Biochemical and... 371
54. Rossetti, G. G., et al. (2022). Non-covalent SARS-CoV-2 Mpro inhibitors developed from in
silico screen hits. Scientific Reports, 12, 2505.
55. Gorny, H., et al. (2023). Combining nano-differential scanning fluorimetry and microscale
thermophoresis to investigate VDAC1 interaction with small molecules. Journal of Enzyme
Inhibition and Medicinal Chemistry, 38, 2121821.
56. Schneider, G. (2018). Automating drug discovery. Nature Reviews. Drug Discovery, 17,
97–113.
57. Batool, M., Ahmad, B., & Choi, S. (2019). A structure-based drug discovery paradigm.
International Journal of Molecular Sciences, 20, 2783.
58. Vázquez, J., López, M., Gibert, E., Herrero, E., & Luque, F. J. (2020). Merging ligand-based
and structure-based methods in drug discovery: An overview of combined virtual screening
approaches. Molecules, 25, 4723.
59. Azevedo, L., Serafim, M. S. M., Maltarollo, V. G., Grabrucker, A. M., & Granato, D. (2022).
Atherosclerosis fate in the era of tailored functional foods: Evidence-based guidelines elicited
from structure- and ligand-based approaches. Trends in Food Science & Technology, 128,
75–89.
60. Lima, A. N., et al. (2016). Use of machine learning approaches for novel drug discovery.
Expert Opinion on Drug Discovery, 11, 225–239.
61. Bosc, N., et al. (2019). Large scale comparison of QSAR and conformal prediction methods
and their applications in drug discovery. Journal of Cheminformatics, 11,4.
62. Réau, M., Langenfeld, F., Zagury, J.-F., Lagarde, N., & Montes, M. (2018). Decoys selection
in benchmarking datasets: Overview and perspectives. Frontiers in Pharmacology, 9, 11.
63. Asse Junior, L. R., et al. (2020). Virtual screening of antibacterial compounds by similarity
search of Enoyl-ACP reductase (FabI) inhibitors. Future Medicinal Chemistry, 12,51–68.
64. Lu, X., et al. (2018). The development of pharmacophore modeling: Generation and recent
applications in drug discovery. Current Pharmaceutical Design, 24, 3424–3439.
65. Hayek-Orduz, Y., et al. (2022). Novel covalent and non-covalent complex-based
pharmacophore models of SARS-CoV-2 main protease (Mpro) elucidated by microsecond
MD simulations. Scientific Reports, 12, 14030.
66. Bouback, T. A., et al. (2021). Pharmacophore-based virtual screening, quantum mechanics
calculations, and molecular dynamics simulation approaches identified potential natural
antiviral drug candidates against MERS-CoV S1-NTD. Molecules, 26, 4961.
67. Cerón-Carrasco, J. P. (2022). When virtual screening yields inactive drugs: Dealing with false
theoretical friends. ChemMedChem, 17, e202200278.
68. Zhu, T., et al. (2013). Hit identification and optimization in virtual screening: Practical
recommendations based on a critical literature analysis. Journal of Medicinal Chemistry, 56,
6560–6572.
69. Yan, X. C., et al. (2020). Augmenting hit identification by virtual screening techniques in
small molecule drug discovery. Journal of Chemical Information and Modeling, 60,
4144–4152.
70. Hevener, K. E., et al. (2018). Chapter Twelve – Hit-to-lead: Hit validation and assessment. In
C. A. Lesburg (Ed.), Methods in enzymology (Vol. 610, pp. 265–309). Academic.
71. Wadman, M. (2023). FDA no longer has to require animal testing for new drugs. Science, 379.
72. Stiefl, N., et al. (2015). FOCUS—Development of a global communication and modeling
platform for applied and computational medicinal chemists. Journal of Chemical Information
and Modeling, 55, 896–908.
73. Serafim, M. S. M., Dos Santos Júnior, V. S., Gertrudes, J. C., Maltarollo, V. G., & Honorio,
K. M. (2021). Machine learning techniques applied to the drug design and discovery of new
antivirals: A brief look over the past decade. Expert Opinion on Drug Discovery, 16, 961–975.
74. Schuller, M., et al. (2021). Fragment binding to the Nsp3 macrodomain of SARS-CoV-2
identified through crystallographic screening and computational docking. Science Advances,
7, eabf8711.
372 M. Sá Magalhães Serafim et al.
75. Gahbauer, S., et al. (2023). Iterative computational design and crystallographic screening
identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2. Proceedings of
the National Academy of Sciences, 120, e2212931120.
76. Owen, D. R., et al. (2021). An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the
treatment of COVID-19. Science, 374, 1586–1593.
77. Boby, M. L. et al. (2023). Open Science discovery of potent non-covalent SARS-CoV-2 main
protease inhibitors. 2020.10.29.339317 Preprint at https://doi.org/10.1101/2020.10.29.339317
78. Kronenberger, T., Laufer, S. A., & Pillaiyar, T. (2023). COVID-19 therapeutics: Smallmolecule drug development targeting SARS-CoV-2 main protease. Drug Discovery Today,
28, 103579.
79. Jin, Z., et al. (2020). Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors.
Nature, 582, 289–293.
80. Mathai, N., Chen, Y., & Kirchmair, J. (2020). Validation strategies for target prediction
methods. Briefings in Bioinformatics, 21, 791–802.
81. Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007). Drug—target
network. Nature Biotechnology, 25, 1119–1126.
82. Chaudhari, R., Tan, Z., Huang, B., & Zhang, S. (2017). Computational polypharmacology: A
new paradigm for drug discovery. Expert Opinion on Drug Discovery, 12, 279–291.
83. Proschak, E., Stark, H., & Merk, D. (2019). Polypharmacology by design: A medicinal
chemist’s perspective on multitargeting compounds. Journal of Medicinal Chemistry, 62,
420–444.
84. Kurosaki, K., Wu, R., & Uesawa, Y. (2020). A toxicity prediction tool for potential agonist/
antagonist activities in molecular initiating events based on chemical structures. International
Journal of Molecular Sciences, 21, 7853.
85. Wu, Z., Li, W., Liu, G., & Tang, Y. (2018). Network-based methods for prediction of drugtarget interactions. Frontiers in Pharmacology, 9.
86. Fernández, A., & Scott, L. R. (2016). Drug leads for interactive protein targets with unknown
structure. Drug Discovery Today, 21, 531–535.
87. Bisswanger, H. (2014). Enzyme assays. Perspectives in Science, 1,41–55.
88. Acker, M. G., & Auld, D. S. (2014). Considerations for the design and reporting of enzyme
assays in high-throughput screening applications. Perspectives in Science, 1,56–73.
89. Sternke, M., Tripp, K. W., & Barrick, D. (2019). Consensus sequence design as a general
strategy to create hyperstable, biologically active proteins. Proceedings of the National
Academy of Sciences, 116, 11275–11284.
90. Chen, Y., & Nielsen, J. (2019). Energy metabolism controls phenotypes by protein ef
and allocation. Proceedings of the National Academy of Sciences, 116, 17592–17597.
91. Li, F., et al. (2022). Deep learning-based kcat prediction enables improved enzymeconstrained model reconstruction. Nature Catalysis, 5, 662–672.
92. Davidi, D., et al. (2016). Global characterization of in vivo enzyme catalytic rates and their
correspondence to in vitro kcat measurements. Proceedings of the National Academy of
Sciences, 113, 3401–3406.
93. Kroll, A., Rousset, Y., Hu, X.-P., Liebrand, N. A., & Lercher, M. J. (2023). Turnover number
predictions for kinetically uncharacterized enzymes using machine and deep learning. Nature
Communications, 14, 4139.
94. Lerman, J. A., et al. (2012). In silico method for modelling metabolism and gene product
expression at genome scale. Nature Communications, 3, 929.
95. Dourado, H., Liebermeister, W., Ebenhöh, O., & Lercher, M. J. (2023). Mathematical properties of optimal fluxes in cellular reaction networks at balanced growth. PLoS Computational
Biology, 19, e1011156.
96. Yang, M., et al. (2018). Functional and informatics analysis enables glycosyltransferase
activity prediction. Nature Chemical Biology, 14, 1109–1117.
97. Dalkiran, A., et al. (2018). ECPred: A tool for the prediction of the enzymatic functions of
protein sequences based on the EC nomenclature. BMC Bioinformatics, 19, 334.
ficiency
12 Experimental Assays: Chemical Properties, Biochemical and... 373
98. Drula, E., et al. (2022). The carbohydrate-active enzyme database: Functions and literature.
Nucleic Acids Research, 50, D571–D577.
99. Rudolf, A. F., Skovgaard, T., Knapp, S., Jensen, L. J., & Berthelsen, J. (2014). A comparison
of protein kinases inhibitor screening methods using both enzymatic activity and binding
affinity determination. PLoS One, 9, e98800.
100. Metz, J. T., et al. (2011). Navigating the kinome. Nature Chemical Biology, 7, 200–202.
101. Stenton, G. R., et al. (2013). Characterization of AQX-1125, a small-molecule SHIP1 activator. British Journal of Pharmacology, 168, 1506–1518.
102. Di Cera, E. (2009). Serine proteases. IUBMB Life, 61, 510–515.
103. Santos, L. H., et al. (2023). Evaluating known Zika virus NS2B-NS3 protease inhibitor
scaffolds via in Silico screening and biochemical assays. Pharmaceuticals, 16, 1319.
104. Kronenberger, T., Sá Magalhães Serafim, M., Kumar Tonduru, A., Gonçalves Maltarollo, V.,
& Poso, A. (2021). Ligand accessibility insights to the dengue virus NS3-NS2B protease
assessed by long-timescale molecular dynamics simulations. ChemMedChem, 16, 2524–2534.
105. Poverennaya, E., Kiseleva, O., Romanova, A., & Pyatnitskiy, M. (2020). Predicting functions
of uncharacterized human proteins: From canonical to Proteoforms. Genes, 11, 677.
106. Robinson, S. L., Smith, M. D., Richman, J. E., Aukema, K. G., & Wackett, L. P. (2020).
Machine learning-based prediction of activity and substrate specificity for OleA enzymes in
the thiolase superfamily. Synthetic Biology, 5, ysaa004.
107. Li, Y., et al. (2018). DEEPre: Sequence-based enzyme EC number prediction by deep
learning. Bioinformatics, 34, 760–769.
108. Zou, Z., Tian, S., Gao, X., & Li, Y. (2019). mlDEEPre: Multi-functional enzyme function
prediction with hierarchical multi-label deep learning. Frontiers in Genetics, 9.
109. Mou, Z., et al. (2021). Machine learning-based prediction of enzyme substrate scope: Application to bacterial nitrilases. Proteins: Structure, Function, and Bioinformatics, 89, 336–347.
110. Safaei, J., Maňuch, J., Gupta, A., Stacho, L., & Pelech, S. (2011). Prediction of 492 human
protein kinase substrate specificities. Proteome Science, 9, S6.
111. Chen, M., et al. (2023). GPS 6.0: An updated server for prediction of kinase-specific phosphorylation sites in proteins. Nucleic Acids Research, 51, W243–W250.
112. Kozakov, D., et al. (2015). The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. Nature Protocols, 10, 733–755.
113. Dennis, S., Kortvelyesi, T., & Vajda, S. (2002). Computational mapping identifies the binding
sites of organic solvents on proteins. Proceedings of the National Academy of Sciences, 99,
4290–4295.
’Donoghue, A. J., et al. (2012). Global identification of peptidase specificity by multiplex
114. O
substrate profiling. Nature Methods, 9, 1095–1100.
115. Lapek, J. D., et al. (2019). Quantitative multiplex substrate profiling of peptidases by mass
spectrometry. Molecular & Cellular Proteomics, 18, 968–981.
116. Yoon, M. C., et al. (2021). Selective neutral pH inhibitor of Cathepsin B designed based on
cleavage preferences at cytosolic and lysosomal pH conditions. ACS Chemical Biology, 16,
1628–1643.
117. Rohweder, P. J., Jiang, Z., Hurysz, B. M., O’Donoghue, A. J., & Craik, C. S. (2023).
Chapter Twelve – Multiplex substrate profi ling by mass spectrometry for proteases. In A. K.
Shukla (Ed.), Methods in enzymology (Vol. 682, pp. 375–411). Academic.
118. Mahoney, M., et al. (2021). A novel class of TMPRSS2 inhibitors potently block SARS-CoV2 and MERS-CoV viral entry and protect human epithelial lung cells. Proceedings of the
National Academy of Sciences, 118, e2108728118.
119. McGovern, S. L., Helfand, B. T., Feng, B., & Shoichet, B. K. (2003). A specific mechanism of
nonspecific inhibition. Journal of Medicinal Chemistry, 46, 4265–4272.
120. Huang, F., Han, X., Xiao, X., & Zhou, J. (2022). Covalent warheads targeting cysteine
residue: The promising approach in drug development. Molecules, 27, 7728.
121. Mellott, D. M., et al. (2021). A clinical-stage cysteine protease inhibitor blocks SARS-CoV-2
infection of human and monkey cells. ACS Chemical Biology, 16, 642–650.
374 M. Sá Magalhães Serafim et al.
122. Jin, Z., et al. (2020). Structural basis for the inhibition of SARS-CoV-2 main protease by
antineoplastic drug carmofur. Nature Structural and Molecular Biology, 27, 529–532.
123. Greasley, S. E., et al. (2022). Structural basis for the in vitro efficacy of nirmatrelvir against
SARS-CoV-2 variants. Journal of Biological Chemistry, 298, 101972.
124. Abriata, L. A., & Dal Peraro, M. (2015). Assessing the potential of atomistic molecular
dynamics simulations to probe reversible protein-protein recognition and binding. Scientific
Reports, 5, 10549.
125. Alamri, M. A., et al. (2021). Pharmacoinformatics and molecular dynamics simulation studies
reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease
3CLpro. Journal of Biomolecular Structure and Dynamics, 39, 4936–4948.
126. Tuley, A., & Fast, W. (2018). The taxonomy of covalent inhibitors. Biochemistry, 57,
3326–3337.
127. Ghosh, A. K., Samanta, I., Mondal, A., & Liu, W. R. (2019). Covalent inhibition in drug
discovery. ChemMedChem, 14, 889–906.
128. Boike, L., Henning, N. J., & Nomura, D. K. (2022). Advances in covalent drug discovery.
Nature Reviews. Drug Discovery, 21, 881–898.
129. Weerapana, E., et al. (2010). Quantitative reactivity profiling predicts functional cysteines in
proteomes. Nature, 468, 790–795.
130. Wu, X., Kriz, A. J., & Sharp, P. A. (2014). Target specificity of the CRISPR-Cas9 system.
Quantitative Biology, 2,59–70.
131. Strohkendl, I., Saifuddin, F. A., Rybarski, J. R., Finkelstein, I. J., & Russell, R. (2018). Kinetic
basis for DNA target specificity of CRISPR-Cas12a. Molecular Cell, 71, 816–824.e3.
132. Krippendorff, B.-F., Neuhaus, R., Lienau, P., Reichel, A., & Huisinga, W. (2009).
Mechanism-based inhibition: Deriving KI and kinact directly from time-dependent IC50
values. Journal of Biomolecular Screening, 14, 913–923.
133. Strelow, J. M. (2017). A perspective on the kinetics of covalent and irreversible inhibition.
SLAS Discovery, 22,3–20.
134. Mons, E., Roet, S., Kim, R. Q., & Mulder, M. P. C. (2022). A comprehensive guide for
assessing covalent inhibition in enzymatic assays illustrated with kinetic simulations. Current
Protocols, 2, e419.
135. Harris, C. M., et al. (2018). Merits and pitfalls in the characterization of covalent inhibitors of
Bruton’s tyrosine kinase. SLAS Discovery, 23, 1040–1050.
136. Palmer, D. S., & Mitchell, J. B. O. (2014). Is experimental data quality the limiting factor in
predicting the aqueous solubility of druglike molecules? Molecular Pharmaceutics, 11,
2962–2972.
137. Popa-Burke, I., & Russell, J. (2014). Compound precipitation in high-concentration DMSO
solutions. Journal of Biomolecular Screening, 19, 1302–
138. Baell, J. B., & Nissink, J. W. M. (2018). Seven year itch: Pan-assay interference compounds
(PAINS) in 2017—Utility and limitations. ACS Chemical Biology, 13,36–44.
139. Borrel, A., et al. (2020). High-throughput screening to predict chemical-assay interference.
Scientific Reports, 10, 3986.
140. Jadhav, A., et al. (2010). Quantitative analyses of aggregation, autofluorescence, and reactivity
artifacts in a screen for inhibitors of a thiol protease. Journal of Medicinal Chemistry, 53,
37–51.
141. Babaoglu, K., et al. (2008). Comprehensive mechanistic analysis of hits from high-throughput
and docking screens against β-lactamase. Journal of Medicinal Chemistry, 51, 2502–2511.
142. Feng, B. Y., & Shoichet, B. K. (2006). A detergent-based assay for the detection of promiscuous inhibitors. Nature Protocols, 1, 550–553.
143. Shoichet, B. K. (2006). Screening in a spirit haunted world. Drug Discovery Today, 11,
607–615.
144. Falke, S., & Betzel, C. (2019). Dynamic light scattering (DLS). In A. S. Pereira, P. Tavares, &
P. Limão-Vieira (Eds.), Radiation in bioanalysis: Spectroscopic techniques and theoretical
methods (pp. 173–193). Springer International Publishing.
1308.
12 Experimental Assays: Chemical Properties, Biochemical and... 375
145. Lorber, B., Fischer, F., Bailly, M., Roy, H., & Kern, D. (2012). Protein analysis by dynamic
light scattering: Methods and techniques for students. Biochemistry and Molecular Biology
Education, 40, 372–382.
146. mic.0.045005-0.
147. Irwin, J. J., et al. (2015). An aggregation advisor for ligand discovery. Journal of Medicinal
Chemistry, 58, 7076–7087.
148. Seidler, J., McGovern, S. L., Doman, T. N., & Shoichet, B. K. (2003). Identification and
prediction of promiscuous aggregating inhibitors among known drugs. Journal of Medicinal
Chemistry, 46, 4477–4486.
149. Kamiloglu, S., Sari, G., Ozdal, T., & Capanoglu, E. (2020). Guidelines for cell viability assays.
Food Frontiers, 1, 332–349.
150. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to
proliferation and cytotoxicity assays. Journal of Immunological Methods, 65,55–63.
151. Roehm, N. W., Rodgers, G. H., Hatfield, S. M., & Glasebrook, A. L. (1991). An improved
colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT.
Journal of Immunological Methods, 142, 257–265.
152. Hu, V. W., Black, G. E., Torres-Duarte, A., & Abramson, F. P. (2002). 3H-thymidine is a
defective tool with which to measure rates of DNA synthesis. The FASEB Journal, 16,
1456–1457.
153. Crane, A. M., & Bhattacharya, S. K. (2013). The use of bromodeoxyuridine incorporation
assays to assess corneal stem cell proliferation. Methods in Molecular Biology, 1014,65–70.
154. Strober, W. (2015). Trypan blue exclusion test of cell viability. Current Protocols in Immu-
nology, 111, A3.B.1–A3.B.3.
155. O’Brien, J., Wilson, I., Orton, T., & Pognan, F. (2000). Investigation of the Alamar Blue
(resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. European
Journal of Biochemistry, 267, 5421–5426.
156. Stockert, J. C., Horobin, R. W., Colombo, L. L., & Blázquez-Castro, A. (2018). Tetrazolium
salts and formazan products in cell biology: Viability assessment, fluorescence imaging, and
labeling perspectives. Acta Histochemica, 120, 159–167.
157. Riss, T. L., Moravec, R. A., Duellman, S. J., & Niles, A. L. (2021). Treating cells as reagents to
design reproducible assays. SLAS Discovery: Advancing the Science of Drug Discovery, 26,
1256–1267.
158. Saotome, K., Morita, H., & Umeda, M. (1989). Cytotoxicity test with simplified crystal violet
staining method using microtitre plates and its application to injection drugs. Toxicology In
Vitro, 3, 317–321.
159. Coban, A. Y. (2014). A new rapid colourimetric method for testing Mycobacterium tuberculosis susceptibility to isoniazid and rifampicin: A crystal violet decolourisation assay.
Memórias do Instituto Oswaldo Cruz, 109, 246–249.
160. Resnick, S. J., et al. (2021). Inhibitors of coronavirus 3CL proteases protect cells from
protease-mediated cytotoxicity. Journal of Virology, 95.
161. Castro, J., et al. (2022). Crystal violet staining alone is not adequate to assess synergism or
antagonism in multi-species biofilms of bacteria associated with bacterial vaginosis. Frontiers
in Cellular and Infection Microbiology, 11.
162. Almutary, A., & Sanderson, B. J. S. (2016). The MTT and crystal violet assays: Potential
confounders in nanoparticle toxicity testing. International Journal of Toxicology, 35,
454–462.
163. Kotz, J. (2012). Phenotypic screening, take two. Science-Business eXchange, 5, 380–380.
164. Priest, B. T., & Erdemli, G. (2014). Phenotypic screening in the 21st century. Frontiers in
Pharmacology, 5.
165. Moffat, J. G., Rudolph, J., & Bailey, D. (2014). Phenotypic screening in cancer drug
discovery—Past, present and future. Nature Reviews. Drug Discovery, 13, 588–602.
166. Idakwo, G., et al. (2018). A review on machine learning methods for in silico toxicity
prediction. Journal of Environmental Science and Health, Part C, 36, 169–191.
376 M. Sá Magalhães Serafim et al.
167. Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017). Opportunities and
challenges in phenotypic drug discovery: An industry perspective. Nature Reviews. Drug
Discovery, 16, 531–543.
168. Vincent, F., et al. (2022). Phenotypic drug discovery: Recent successes, lessons learned and
new directions. Nature Reviews. Drug Discovery, 21, 899–914.
169. Frye, S. V. (2010). The art of the chemical probe. Nature Chemical Biology, 6, 159–161.
170. Quinlan, R. B. A., & Brennan, P. E. (2021). Chemogenomics for drug discovery: Clinical
molecules from open access chemical probes. RSC Chemical Biology, 2, 759–795.
171. . (2022). A conversation on using chemical probes to study protein function in cells and
organisms. Nature Communications, 13, 3757.
172. Arrowsmith, C. H., et al. (2015). The promise and peril of chemical probes. Nature Chemical
Biology, 11, 536–541.
173. Dale, N. C., Johnstone, E. K. M., White, C. W., & Pfleger, K. D. G. (2019). NanoBRET: The
bright future of proximity-based assays. Frontiers in Bioengineering and Biotechnology, 7.
174. Hall, M. P., et al. (2012). Engineered luciferase reporter from a deep sea shrimp utilizing a
novel Imidazopyrazinone substrate. ACS Chemical Biology, 7, 1848–1857.
175. Machleidt, T., et al. (2015). NanoBRET—A novel BRET platform for the analysis of protein–
protein interactions. ACS Chemical Biology, 10, 1797–1804.
176. Shenoy, N., et al. (2017). Drugs with anti-oxidant properties can interfere with cell viability
measurements by assays that rely on the reducing property of viable cells. Laboratory
Investigation, 97, 494–497.
177. Simeonov, A., et al. (2008). Fluorescence spectroscopic profiling of compound libraries.
Journal of Medicinal Chemistry, 51, 2363–2371.
178. Thorne, N., et al. (2012). Firefly luciferase in chemical biology: A compendium of inhibitors,
mechanistic evaluation of chemotypes, and suggested use as a reporter. Chemistry & Biology,
19, 1060–1072.
179. Gul, S., & Gribbon, P. (2010). Exemplification of the challenges associated with utilising
fluorescence intensity based assays in discovery. Expert Opinion on Drug Discovery, 5,
681–690.
180. Zhang, X. D., Wang, D., Sun, S., & Zhang, H. (2021). Issues of Z-factor and an approach to
avoid them for quality control in high-throughput screening studies. Bioinformatics, 36,
5299–5303.
181. Zhang, J. H., Chung, T. D., & Oldenburg, K. R. (1999). A simple statistical parameter for use
in evaluation and validation of high throughput screening assays. Journal of Biomolecular
Screening, 4,67–
182. Präbst, K., Engelhardt, H., Ringgeler, S., & Hübner, H. (2017). Basic Colorimetric Proliferation Assays: MTT, WST, and Resazurin. In D. F. Gilbert & O. Friedrich (Eds.), Cell viability
assays: Methods and protocols (pp. 1–17). Springer.
183. Dahlin, J. L., et al. (2015). Post-HTS case report and structural alert: Promiscuous 4-aroyl-1,5disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR. Bioorganic &
Medicinal Chemistry Letters, 25, 4740–4752.
184. Su, B.-H., et al. (2015). Rule-based classification models of molecular autofluorescence.
Journal of Chemical Information and Modeling, 55, 434–445.
185. Baell, J. B., & Holloway, G. A. (2010). New substructure filters for removal of pan assay
interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.
Journal of Medicinal Chemistry, 53, 2719–2740.
186. Magalhães, P. R., Reis, P. B. P. S., Vila-Viçosa, D., Machuqueiro, M., & Victor, B. L. (2021).
Identification of Pan-Assay INterference compoundS (PAINS) using an MD-based protocol.
In I. S. Moreira, M. Machuqueiro, & J. Mourão (Eds.), Computational design of membrane
proteins (pp. 263–271). Springer US.
187. Nelson, K. M., et al. (2017). The essential medicinal chemistry of curcumin. Journal of
Medicinal Chemistry, 60, 1620–1637.
73.